Glox Therapeutics

Glox Therapeutics is an Oxford, UK-based biotech developing a novel class of precision antibiotics called engineered bacteriocins to address the critical global threat of antimicrobial resistance. Built on a proprietary discovery platform derived from two decades of academic research, the company is advancing a pipeline targeting high-priority, multidrug-resistant Gram-negative pathogens. As a private, preclinical-stage company, Glox aims to deliver targeted, narrow-spectrum therapeutics that could overcome existing resistance mechanisms and improve patient outcomes in serious hospital-acquired infections.

Proprietary discovery platform for engineering precision protein bacteriocins, built on over 20 years of research into their structure and function.

Glox competes with other biotechs developing novel anti-infectives (e.g., phage therapy, antibodies, new small molecules) for resistant Gram-negative infections. Its differentiation lies in the precision targeting of its engineered bacteriocin platform, aiming for specificity that avoids broad microbiome disruption.